\
&
Contact us
\
&
Contact us
Published on | 4 years ago
ProgrammesIn the past weeks the Excel files with the call topics overview have had some issues and were not complete. Apparently some call topics were missing in the file.
This has been resolved and the latest version is now available on the NCP website with currently 993 call topics.
What is the 'Call topics overview'?
It goes without saying, the main sources of information on the call topics are the Funding & Tenders Portal and the Work Programmes.
However, sometimes you are just in need of a good overview to quickly find back relevant information or to follow-up certain initiatives in your organisation. This is why NCP Flanders provides, as an extra service, Excel files with the essential call topic information. For now, this exists in 2 variants, and the information in both is exactly the same:
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Agro-Food, Environment
The Sustainable Blue Economy Partnership brings together 74 partner institutions from 32 countries and the European Commission under Horizon Europe. They have recently opened a new transnational access call to marine and maritime research infrastructures with several intermediary deadlines. The next cut-off is 20 October 2026 at 11:00 CEST. T... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
